Business Context and Reporting Period
This Form 8-K is a current report filed by Cerecor Inc. (noting a discrepancy with the provided metadata company name "Avalo Therapeutics, Inc.") on March 17, 2021. The registrant is a Delaware corporation with its principal executive offices in Rockville, Maryland, and its common stock trades on the Nasdaq Capital Market under the symbol CERC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document references an attached Investor Presentation (Exhibit 99.1) which contains estimated cash and cash equivalents as of February 28, 2021, but the numerical data is not included in the text of this report.
Material Changes
No material changes to financial results or operations are detailed in the text of this filing. The report serves solely to announce the release of an updated investor presentation.
Guidance, Outlook, and Risks
- Event: The Company released an updated Investor Presentation on March 17, 2021, intended for use in meetings with investors.
- Forward-Looking Statements: The filing contains forward-looking statements regarding estimated cash and cash equivalents. The Company warns that actual results may differ materially due to various risks.
- Risk Factors: Investors are directed to the Company's Annual Report on Form 10-K for the year ended December 31, 2020, specifically under "Part I, Item 1A - Risk Factors" and "Part II, Item 7 - Management's Discussion and Analysis," for a detailed discussion of uncertainties.
Investor Verification Checklist
- Verify the correct registrant name (Cerecor Inc. vs. Avalo Therapeutics, Inc.) to ensure the correct company is being analyzed.
- Review the attached Exhibit 99.1 (Investor Presentation) for the specific estimated cash and cash equivalents as of February 28, 2021, as these figures are not in the main text.
- Consult the 2020 Form 10-K for comprehensive risk factors and historical financial data referenced in this report.